Published in Diabetes Care on May 01, 2011
VEGF and podocytes in diabetic nephropathy. Semin Nephrol (2012) 1.02
Increased inner ear susceptibility to noise injury in mice with streptozotocin-induced diabetes. Diabetes (2012) 0.97
Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db/db mice. PLoS One (2014) 0.85
Effect of uncontrolled hyperglycemia on levels of adhesion molecules in patients with diabetes mellitus type 2. J Zhejiang Univ Sci B (2015) 0.82
Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy. PLoS One (2014) 0.82
Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr Nephrol (2014) 0.79
Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice. J Am Soc Nephrol (2014) 0.78
Endothelial and platelet markers in diabetes mellitus type 2. World J Diabetes (2015) 0.78
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Adiponectin and adiponectin receptors. Endocr Rev (2005) 8.46
Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet (1982) 6.93
Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia (1989) 5.68
Signaling vascular morphogenesis and maintenance. Science (1997) 4.55
Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med (2006) 4.26
Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes (2004) 4.24
Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev (2008) 3.49
VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer (2008) 3.02
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol (2006) 2.51
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care (2010) 2.40
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26
Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell (2008) 2.13
Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol (2007) 2.06
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol (2007) 1.92
Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx. Cardiovasc Res (2009) 1.80
Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab (2003) 1.75
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes (2006) 1.74
Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol (2010) 1.64
VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol (2007) 1.61
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int (2006) 1.59
Abnormal angiogenesis in diabetic nephropathy. Diabetes (2009) 1.53
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol (2006) 1.51
Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int (2005) 1.45
Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int (2005) 1.41
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int (2006) 1.37
Glomerular sieving coefficient of serum albumin in the rat: a two-photon microscopy study. Am J Physiol Renal Physiol (2009) 1.37
Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol (2005) 1.28
Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care (2004) 1.28
Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes (2004) 1.23
Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes (2008) 1.21
Revisiting the rosiglitazone story--lessons learned. N Engl J Med (2010) 1.21
New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol (2004) 1.17
Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol (2007) 1.17
Vascular endothelial growth factor and diabetic nephropathy. Curr Diab Rep (2008) 1.13
Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis (2005) 1.11
Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care (1999) 1.11
The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int (2009) 1.08
Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol (2008) 1.07
Flow-dependent regulation of angiopoietin-2. J Cell Physiol (2008) 1.05
Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol (2002) 1.03
Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond) (2009) 1.03
Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol (2007) 1.02
Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant (2004) 1.01
Decreased circulating CD34+ cells are associated with progression of diabetic nephropathy. Diabet Med (2009) 1.00
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int Suppl (1997) 0.93
Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract (2010) 0.91
Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care (2010) 0.88
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis (2009) 0.84
Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res (2007) 0.83
Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol Res (2006) 0.82
Molecular mechanisms of proteinuria in diabetes. Biochem Soc Trans (2008) 0.80
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet (2010) 2.55
Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol (2007) 2.06
Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury. Kidney Int (2008) 1.70
IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism. Kidney Int (2003) 1.43
Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes (2008) 1.21
Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol (2008) 1.07
Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol (2005) 1.04
A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension (2012) 0.98
Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol (2013) 0.98
Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant (2009) 0.98
Albuminuria is associated with too few glomeruli and too much testosterone. Kidney Int (2013) 0.93
Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. PLoS One (2012) 0.90
Fluorescence-based sensing of glucose using engineered glucose/galactose-binding protein: a comparison of fluorescence resonance energy transfer and environmentally sensitive dye labelling strategies. Biochem Biophys Res Commun (2007) 0.89
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Clin J Am Soc Nephrol (2013) 0.89
An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension (2014) 0.89
Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care (2010) 0.88
Glucose induces increases in levels of the transcriptional repressor Id2 via the hexosamine pathway. Am J Physiol Endocrinol Metab (2005) 0.86
VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Metabolism (2012) 0.85
N-3 PUFA increase bioavailability and function of endothelial progenitor cells. Food Funct (2014) 0.83
Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes. Clin J Am Soc Nephrol (2012) 0.81
Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol (2010) 0.81
Non-invasive glucose monitoring by NAD(P)H autofluorescence spectroscopy in fibroblasts and adipocytes: a model for skin glucose sensing. Diabetes Technol Ther (2003) 0.80
ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant (2008) 0.80
Circulating vascular progenitor cells and central arterial stiffness in polycystic ovary syndrome. PLoS One (2011) 0.79
Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Med Rep (2010) 0.78
High prevalence of cardio-metabolic risk factors in a young urban Sri-Lankan population. PLoS One (2012) 0.78
Influence of depression and anxiety on circulating endothelial progenitor cells in patients with acute coronary syndromes. Hum Psychopharmacol (2015) 0.77
Future strategies to prevent renal microvascular disease complications in diabetes. Future Cardiol (2008) 0.77
Podocytes and the struggle against glucose toxicity: new targets for treatment? Metabolism (2012) 0.75
DIABRISK-SL prevention of cardio-metabolic disease with life style modification in young urban Sri Lankan's--study protocol for a randomized controlled trial. Trials (2011) 0.75
Serum intact parathyroid hormone in diabetic patients on haemodialysis: what is the treatment goal? Nephrol Dial Transplant (2007) 0.75
The link between mechanical stretch and glucose metabolism--a conceptual advance in understanding diabetic (and non diabetic?) renal disease. Nephrol Dial Transplant (2006) 0.75